Aegle Therapeutics

MSC-derived extracellular vesicles, cell-free therapy, regenerative medicine

repairingextracellular vesicle

aegletherapeutics.com·Miami, Florida, United States·

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-WZUK

Projects

AGLE-102 for dystrophic epidermolysis bullosa

undisclosed

drug program · high · Tue Aug 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Treat recessive dystrophic epidermolysis bullosa and other severe dermatological disorders using MSC-derived extracellular vesicles with regenerative, immunomodulatory, and anti-inflammatory effects.

Cell-free therapy based on mesenchymal stem cell-derived extracellular vesicles; clinical study listed as MSC EVs in dystrophic epidermolysis bullosa.

ClinicalTrials.gov record NCT04173650 for MSC EVs in dystrophic epidermolysis bullosa, published 2024-08-13 in supplied records.

Extracellular vesicles for burn wounds

phase 1

drug program · medium · Thu Aug 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time)

Improve healing of deep second-degree burn wounds using extracellular vesicles derived from bone marrow mesenchymal stem cells.

Treatment of burn wounds with extracellular vesicles isolated from bone marrow-derived mesenchymal stem cells; associated publication described as a phase 1 dose-escalation clinical trial.

ClinicalTrials.gov record NCT05078385 for safety of extracellular vesicles for burn wounds, published 2023-08-10 in supplied records.

The supplied 2022 publication title states that mesenchymal stem cells improved healing of burn wounds in a phase 1 dose-escalation clinical trial, but no abstract or detailed outcomes were supplied.

MSC-derived extracellular vesicle therapy platform

exploratory

platform · high · Fri Jan 01 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Develop cell-free extracellular vesicle therapies that deliver natural biomolecular payloads for regenerative, immunomodulatory, and anti-inflammatory effects in rare dermatological diseases.

Platform based on MSC-derived extracellular vesicles, supported by proteomic characterization of bone marrow-derived MSC extracellular vesicles and studies of type VII collagen transfer to RDEB fibroblasts.

Supplied publications include 2021 proteomic analysis of bone marrow-derived MSC extracellular vesicles and 2018 evidence of type VII collagen transfer to RDEB fibroblasts.

Supplied publication titles indicate EV characterization relevant to proliferation, angiogenesis, Wnt signaling, basement membrane biology, and type VII collagen transfer to RDEB fibroblasts; detailed results were not supplied.

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence